1 / 11

Anti-Diabetic Pharmaceuticals Market in India 2012

Bharatbook.com introduces a new report on " Anti-Diabetic Pharmaceuticals Market in India 2012 " provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. It also provides a global diabetes map.

bharatbookseo
Télécharger la présentation

Anti-Diabetic Pharmaceuticals Market in India 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. I Anti-Diabetic Pharmaceuticals Market - India March 2012

  2. Executive Summary Global Market of Anti-diabetic pharmaceuticals is expected to growth at a CAGR of X% for 2010 - 2015 period Anti-diabetic pharmaceuticals market in India is valued at INR xx units in 20-- Market Market is expected to grow at a CAGR of m% from 20-- to 20-- Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology Drivers: Challenges: Price regulation in insulin market Increase in the number of diabetic Use of complementary and alternative patients Drivers and medicines Challenges Introduction of newer and better drugsIncreasing aging population Maintainence of healthy lifestyle to avoiddiabetes Comprehensive health insurancespolicies covering diabetes Drug Phases of clinical trial Regulation and Approval and licensing of drugs Patents Patents Public Companies Private Companies Company A Company G Company B Company H Competition Company C Company I Company D Company J Company E Company F 2 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  3. •Introduction •Market Overview •Drivers & Challenges •Government Initiatives •Market Value Chain, Regulation andPatents •Competition •Strategic recommendation 3 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  4. India’s diabetes market is poised to grow over the coming years Indian Market - Overview Market Size and Growth • India is considered to be one of the most lucrative diabetes markets in the world INR bn y% F •Anti-diabetics represent the second fastest growing 40 E therapeutic segment among all the segments ,afteroncology C D 30 A B • Market is expected to grow from INR A bn to INR F bn in 20--, at a CAGR of y% 20 •Biguanides, Gliclazide, Gliclazide with metformine, Rosiglitazone and Pioglitazone are the top selling drugs 10 0 in Indian market 20-- 20--e 20--e 20--e 20--e 20--e • Human Mixard 30/70 is the largest selling insulin in Indian market It showed largest growth among the top 10 brands in IndianPharmaceutical market Growth in therapeutic segments(2010) Market Segmentation DrugsInsulin 0 5 10 15 20 25 30 35 % oncology diabetes ab X 1 Y 2 CVSCNS c de X 2 Y 1 respiratory pain f gastro g anti-infectives h Source: 4 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  5. Drivers & Challenges Challenges Price regulation in insulin market Drivers Increase in the number of diabeticpatients Competition from complementary andalternative medicines Introduction of newer and betterdrugs Maintainence of healthy lifestyle toavoid diabetes Increasing aging population Increase in health insurances 5 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  6. Various initiatives taken by the government is providing a boost to this market • ICDC ,registered under Planning Commission, Government of India, is the only organisation inIndia providing doorstep diabetes care • ICDC implements National Doorstep Diabetes Identification and follow-up programme through Grass Root Level NGOs all over India Indian Council for Diabetic Care • ICDC affiliates NGOs as Partner Organisation and reach people who are suffering with Diabetes and help them to control diabetes and live without any complications • ICDC provides free glucometer and 100 Strips to the NGOs to start identifying the diabetes patients even in villages • ICDC is making efforts to provide medical insurance to the diabetes patients through Government of India as in the case of family planning insurance scheme •National Programme for prevention and Control of Diabetes, Cardiovascular diseases and Stroke (NPCDCS) was started in 2008,with the objective of prevention, diagnosis and early management of diabetes NPCDCS • It is already being implemented in 100 most backward and remote districts spread across 21 states • Indian Government plans to extend this programme to all the 650 districts of the country under the 12th five year plan •National Rural Health Mission is providing services for diabetes care in rural India NRHM •Seeks to provide effective healthcare to rural population throughout the country with special focus on 18 states Source: 6 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  7. Major Private Companies - Summary PAT 1,000 Size of the Bubble represents Total Assets in INR XX A 0 -1,000 -2,000 B -3,000 -4,000 -5,000 -6,000 -7,000 -8,000 -9,000 C -10,000 Revenue2,000,000 2,500,000 3,000,000 3,500,000 -11,000 -500,000 0 500,000 1,000,000 1,500,000 A B C 7 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  8. Public: Domestic Company - A Company (1/3) Company Information Offices and Centres - India X Road Corporate Address Bangalore Tel No. +91 xx xxxxx xxxxx Fax No. +91 xx xxxxx xxxxx Website www.ppp.com Year of Incorporation 19-- Ticker Symbol xxxxxx Stock Exchange NNN Products and Services City A Head Office Category Products/Services Key People CVD, CNS, respiratory, dermatology, Pharmaceutical orthopedics, nutritional, urology, anti- Name Designation infectives Person M Founder Infectious diseases, metabolic diseases,inflammatory/respiratory diseases, andoncology MoleculeDevelopment Person N CFOPerson O Head Person Q President Source: 8 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  9. Public: Domestic Company - A Company (2/3) Financial Snapshot Key Ratios Particulars y-o-y change 20-- 20-- 20-- 20-- RevenueINR mn Revenue Profit Profitability Ratios INR mnProfit / Loss q pn0 Operating MarginNet Margin t r s s Profit Before Tax MarginReturn on Equity r p q m n o Return on Capital EmployedReturn on Working CapitalReturn on Assets t -m 0 20-- 20-- 20-- 20-- Financial Summary Return on Fixed Assets Cost Ratios • The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20-- Operating costs (% of Sales)Administration costs (% of Sales) • The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20-- Interest costs (% of Sales) Liquidity Ratios • The company earned an operating margin of x per cent in FY 20-- a decrease of y percentage points over FY 20-- Current RatioCash Ratio • The company reported debt to equity ratio of x in FY 20--, an increase of y per cent over FY 20-- Leverage Ratios Debt to Equity RatioDebt to Capital RatioInterest Coverage Ratio Financial Summary Indicators Present Value Efficiency Ratios Market Capitalization (INR) X mn Fixed Asset TurnoverAsset Turnover Total Enterprise Value (INR) Y mn Current Asset TurnoverWorking Capital Turnover EPS (INR) Z mn PE Ratio (Absolute) A Capital Employed Turnover Source: Improved Decline 9 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  10. Public: Domestic Company - A Company (3/3) Key Business Segments Key Geographic Segments m n o x y z x x x x xx x x y y y y y z z z z z y z y z z y 20-- 20-- 20-- 20-- 20-- 20-- 20-- 20-- Key Recent Developments Description News • Company A is an integrated research based company that produces a wide range of generic medicines Overview • Serves customers in over 100 countries with manufacturing facilities in several countries • Launched Drug M for the treatment of diabetes Diabetes Management • Also manufactures Insulin N under its Diabetes management segment • Is making consistent effort for continual improvement in rural areas with respect to accessibility of medicines Key Initiatives Source: 10 ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT

  11. For more details about the report visit: http://www.bharatbook.com/medical-devices-market-research-reports/adonis-medical-systems-pvt-ltd-company-profile-2011.html http://www.bharatbook.com/healthcare-market-research-reports/anti-diabetic-pharmaceuticals-market-in-india-2012.html Bharat Book Bureau Phone : +91 22 27810772, 27810773 Fax : +91 22 27812290 E-mail : info@bharatbook.com Website : www.bharatbook.com

More Related